InterMune jumps on successful drug trial news
Shares of InterMune Inc. (Nasdaq:ITMN) are higher on news before the opening that a Phase I trial of a drug for the treatment of hepatitis C was successful. The Brisbane, Calif.-based company reported that a trial showed the drug candidate ITMN-191 reduced infection levels and was safe.
At 3:49 p.m. ET, the stock had added $2.57, or 18%, to $17.15. For detailed price information and recent news stories about InterMune, click ITMN.
